Chemicals

Amyris to acquire Oobli, adding fermented sweet proteins to its biomanufacturing platform

Amyris plans to acquire Oobli, pairing its strain engineering and manufacturing scale with fermentation-derived sweet proteins.

Imani NdlovuNovember 16, 20265 min read1 views

Concept illustration of stainless-steel fermentation tanks linked to stylized protein structures and fruit-derived motifs in a clean industrial setting.

Amyris, Inc. announced that it will acquire Oobli Inc., a Davis, California-based developer of fermentation-derived sweet proteins. Amyris said the acquisition would combine its scientific capabilities and manufacturing depth with Oobli’s protein fermentation expertise. The company described the move as a strategic commercial and technology expansion that would accelerate its footprint in protein- and peptide-based solutions across end markets.

Amyris, based in Emeryville, California, describes itself as a vertically integrated biomanufacturing company. Oobli has focused on sweet proteins produced through fermentation; these ingredients are intended to help food and beverage brands reduce sugar while maintaining sweetness. The acquisition follows Amyris’ expansion of manufacturing capacity earlier this year at its advanced fermentation facility in Barra Bonita, Brazil.

Complementary platforms

Kathy Fortmann, Amyris’ chief executive officer, said Oobli offers a commercial and technology platform that complements Amyris’ own. She said the company’s commercial scale and resources could help accelerate adoption of sweet proteins. Fortmann also said that combining Oobli’s protein expertise with Amyris’ strain engineering, manufacturing scale and commercial capabilities could broaden opportunities in food and beverage, personal care, flavor and fragrance, agriculture and other areas.

Amyris said Oobli’s commercial portfolio of sweet proteins will be the first to benefit from the combined platform. According to Oobli, the company has spent the past decade refining a fermentation process for producing sweet proteins that occur naturally in rare fruits and berries found near the equator. Oobli describes its ingredients as the first of their kind in the sugar-reduction category.

How the proteins work

Sweet proteins are reported to be hundreds to thousands of times sweeter than sugar. They bind directly to sweet-taste receptors and are metabolized by the body as protein, according to Oobli. The company says this allows them to deliver sweetness without gut disruption or blood-sugar spikes.

The portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, known scientifically as brazzein, monellin and thaumatin, respectively. Oobli says the ingredients have FDA GRAS status for use as an ingredient and are FEMA GRAS-affirmed for use as a natural flavor. Oobli said the proteins give brands a tool to reduce sugar across sports and nutrition, dairy, beverages, chocolate, bakery and confectionery, amid growing consumer awareness of metabolic health and sugar reduction.

Scale and continuity

Ali Wing, Oobli’s chief executive officer, said the company had long sought a way to deliver the sweet taste consumers want without trade-offs to health and the environment. Wing said joining Amyris would provide the scale and resources needed to pursue the goal of making sweet proteins a standard option in sweetness solutions.

Fortmann said biomanufactured solutions tend to succeed when they align with consumer demand and market needs. She said Oobli’s platform supports sweet taste, sugar reduction and clean-label goals at the same time.

The acquisition is expected to close in the coming weeks. Amyris said all existing customer commitments and brand partnerships will continue to be honored uninterrupted as Oobli’s portfolio expands within Amyris.